OCTIMET partners OMO-1 and OMO-2 with Shanghai Allist Pharmaceuticals Co., Ltd. for Greater China

OMO-1 has potential to treat cancer as a monotherapy and in combination with EGFR TKIs for patients becoming resistant to and progressing on treatment.

Geel, Belgium, 16 September 2020 – OCTIMET Oncology NV, a clinical-stage Belgian life science company with a focus on the development of highly selective, differentiated MET kinase inhibitors, is pleased to announce the licensing of the Greater China rights for its lead clinical compound OMO-1 and a second preclinical asset exclusively to Shanghai Allist Pharmaceuticals Co., Ltd.

OMO-1 is an oral, highly selective small molecule MET kinase inhibitor, that has demonstrated potent single agent and combination activity in a range of preclinical cancer models.

OMO-1 has been evaluated in a monotherapy setting as well as in combination with small molecule EGFR tyrosine kinase inhibitors (TKIs) in Europe, showing a favorable safety profile and early signs of efficacy in MET-selected cancer patients. Allist will drive the clinical development of this compound in China, initially focusing on expanding the combination data with Allist’s third generation EGFR TKI Furmonertinib (AST2818). In China, more than 38% of NSCLC patients harbor activating EGFR mutations, making the region ideal for completing expanded clinical efficacy studies more rapidly whilst addressing a large potential market.

“We are proud to have Shanghai Allist Pharmaceuticals Co., Ltd. as a partner in developing this exciting therapeutic agent” said Shelley Margetson, Chief Executive Officer of OCTIMET. “Development in China is strategically important for OMO-1 and we look forward to seeing the results of the combination studies with Allist’s EGFR TKI compound, thereby making a difference for cancer patients in need of efficacious targeted therapies.”

“MET amplification is known to be a key driver of resistance to EGFR TKIs. We are excited to explore further the combination of OMO-1, a differentiated selective MET kinase inhibitor, with our innovative third generation EGFR TKI Furmonertinib and look forward to generating significant efficacy data that will aim to meet clinical unmet need in providing further treatment for seriously ill cancer patients who have few other therapy options” said Ms. Sandy Mou, the CEO from Allist Pharmaceuticals.

For more information please contact:

Shelley Margetson, CEO
Pieter Van Reysschootlaan 2/104
9051 Sint-Denijs-Westrem (Gent)